How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

1 Recommendations

Closed for comments This consultation ended on at   Request commenting lead permission

1 Recommendations

1.1 Sacituzumab govitecan is not recommended, within its marketing authorisation, as an option for treating unresectable triple-negative locally advanced or metastatic breast cancer in adults after 2 or more systemic therapies, at least one of which was for advanced disease.

1.2 This recommendation is not intended to affect treatment with sacituzumab govitecan that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.

Why the committee made these recommendations

Usual treatment for triple-negative locally advanced or metastatic breast cancer is chemotherapy.

Clinical trial evidence shows that sacituzumab govitecan increases how long people have before their disease gets worse and how long they live compared with chemotherapy.

At its current price, the cost-effectiveness estimates for sacituzumab govitecan are higher than what NICE usually considers an acceptable use of NHS resources. Therefore, it is not recommended.